LearnGlossaryMarketStocksSuperinvestorsSign in

COGT

Cogent Biosciences, Inc.

Healthcare · $5.8B market cap

Verdict

We can't put a fair value on COGT right now. It looks like a preferred share, note or other security rather than ordinary common stock. The figures we receive belong to the parent company, so they can't value this security.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-15.0% a year✗
Sales growth31.5% a year✓
Free cash flow growth—?
Return on invested capital-55.7%✗

Follow COGT

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds COGT. In Q2 2026, 1 added. Who we track

Howard Marks

Oaktree Capital Management · as of Q2 2026

$14.8M

11,890,000 shares

Moves in Q2 2026

Added: Howard Marks

About Cogent Biosciences, Inc.

Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works